Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Crosswalk Therapeutics Inc. maintains a focused active footprint at the USPTO with 1 pending office action. This matter is handled by 1 distinct examiner, CHOWDHURY, IQBAL HOSSAIN. The data shows 0 distinct art units, which reflects a concentrated administrative path for this specific portfolio. This lack of technical diversification suggests that the company's current legal efforts are directed toward a specific goal rather than a broad array of technological classifications.
The busiest examiner, CHOWDHURY, IQBAL HOSSAIN, holds the pending office action, and the busiest examiner pending count is 1. With only the 1 distinct examiner involved, the company experiences no fragmentation in its examiner-facing strategy. This singular focus allows for a direct and consistent approach to resolving the outstanding office action without the need to reconcile different examiner preferences or procedural requirements.
The presence of 0 distinct art units indicates that the portfolio is not currently spread across different administrative divisions at the office. For the practitioner, this means that the active matter represents the sole point of contact and procedural focus for the company's current US patent efforts. Such a structure simplifies the management of deadlines and ensures that all resources are concentrated on a specific prosecution timeline.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHOWDHURY, IQBAL HOSSAIN | 1 | 73.7% | +57.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759313 | ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS | CHOWDHURY, IQBAL HOSSAIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759313 | ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS | CHOWDHURY, IQBAL HOSSAIN | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18759313 | ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS | CHOWDHURY, IQBAL HOSSAIN | — | §102§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial